Alemtuzumab is a humanized monoclonal antibody recently approved for relapsing-remitting multiple sclerosis (MS) treatment. It is highly effective at reducing relapse rate, improving disability outcomes, and decreasing magnetic resonance imaging activity.1 Adverse events include infusion-related reactions, infections, and secondary autoimmune disorders.1,2 We report 2 cases of MS with early neutropenia due to alemtuzumab, an adverse event not previously described, to our knowledge. Both patients signed informed consent.
Gaitán MI, Ysrraelit MC, Correale J. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab. JAMA Neurol. 2017;74(9):1143–1144. doi:10.1001/jamaneurol.2017.1456
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: